

Gavi cholera vaccine programme update

Investments, 5.0 strategy & forecast

Marta Tufet – Head of Policy
Samya Mandal – Senior Analyst, Vaccine Forecasting
Allyson Russell – Cholera & Typhoid Programme Manager

7 December 2021
GTFCC OCV WG Annual Meeting




1

Gavi Investment in OCV & Linkages to 5.0 Strategy

What is the Vaccine Investment Strategy (VIS)? What are its objectives?

- Timeline




- Process



Cholera investment during VIS'18

OCV ranking in 2018 Investment Case



■ Health impact ■ Value for money
■ Equity and social protection
■ Economic impact ■ Global health security

Recommendation

- Investment in planned, preventive vaccination with OCV, shifting away from only financing outbreak response
- Learning agenda on cholera vaccine implementation in disease hotspots

1. Maximum 40pts for health impact (30pts for total deaths averted, 10pts for deaths averted per 100k), 20pts for value for money (cost per death averted), 15pts for equity and social protection impact, 10pts for economic impact and 15pts for global health security

Note: Malaria not up for investment decision. Used as comparator with Health impact and economic impact based on high-level estimates

OCV investment in the context of Gavi 5.0



Pregnant women



Maternal & Newborn



Infant (<12 months)



2nd year of life (13-23 month)



Older children¹ (2-8 years)



Adolescent (9-15 years)



Adults & older people

VIS 2018	RSV	Hep B birth dose	Men ACWXY ² , DTwP Booster	Td Booster	Td Booster
	Rabies PEP, OCV				
Platforms	Antenatal care	Postnatal & postpartum care		School-entry / school-based	
	Multisectoral approaches to disease control (WASH , animal health)				
Global health agendas	Advancing Maternal Immunisation, Rabies Zero by 30, Ending Cholera , Maternal and Neonatal Tetanus Elimination, Global Health Sector Strategy on Viral Hepatitis, Interagency Coordination Group on AM				

- Strong contribution to **equity, social protection, and global health security**
- Strengthening **life course approach** by adding new timepoints
- Provides opportunities for better **cross-platform interventions** (WASH) and **disease control initiatives**

2

OCV Long-Term Forecast


Long term forecast – Strategic Demand Scenarios

Background

- SDS is a long-term forecast (10-15 years) for an antigen aiming to model multiple scenarios of long-term demand trends
- Used to inform various strategic areas of work e.g. vaccine roadmaps, tender strategies, communication with partners, suppliers
- Developed/ updated once in a few years when sufficient shift expected in long-term demand levels

Next steps

- Last SDS was in late 2017 and used to inform the decision on VIS 2018 strategy which recommended investment for preventive vaccination OCV program
- Next update SDS update planned in Q1-Q2 of 2022
- Process includes few rounds of consultations on inputs, assumptions with partners, draft review and finalisation



3

Preventive OCV Programme Design

OCV Programme – Guiding Principles



Health Impact

- Targeted campaigns at sub-national level to maximize impact
- Differentiated strategies based on target population and context
- Leveraging campaigns to integrate WASH activities and identify and vaccinate underimmunized children, and lifecourse vaccines
- Generating evidence to improve future programme delivery strategies



Coordination

- Between actors at the global, regional and country levels to ensure vaccination plans are integrated in country strategies, and are supported by and strengthen routine intervention & immunization systems
- Between ICG, GTFCC, and Gavi to ensure equitable allocation and rapid deployment of vaccines between preventive and emergency programs



Equity

- Prioritizing and reaching those most in need, who are missed by existing cholera control interventions and/or at risk due to living in outbreak-prone areas or amidst humanitarian crises

Goals of an Updated Application Process



Implement a holistic, interactive review to improve **quality** of campaigns and therefore health outcomes

Stakeholder Engagement and Roles



- Primary technical advisor to countries' cholera control planning
- Reviews and endorses NCP, including hotspot vaccination plan.
- Provides TA to develop OCV application
- Allocates OCV based on agreed principles



- Develops application guidelines and tools
- Facilitates application reviews and approvals
- Convenes **Independent Review Committee** to evaluate applications and provide recommendations

Note: ICG remains responsible for management of OCV stockpile for emergency use, including reviewing and providing approval for emergency use applications

THANK YOU

Contact:

Allyson Russell – Cholera & Typhoid Programme Manager
arussell@gavi.org

